SCOLR Pharma, Inc.

109 articles about SCOLR Pharma, Inc.

• SCOLR Pharma, Inc. Announces Issuance of European Patent for CDT&#0174 Ibuprofen

  7/11/2012

• SCOLR Pharma, Inc. Launches Redesigned Website to Support Their CDT&#0174 Formulated Supplements

  6/26/2012

• SCOLR Pharma, Inc. Welcomes Clem Calabrese as Director of Field Sales

  5/1/2012

• SCOLR Pharma, Inc.'s Partner Announces Successful Results in Pivotal Bioequivalence Trial and Plans for a Pre-NDA Meeting

  4/19/2012

• SCOLR Pharma, Inc.'s Partner Announces Positive Preliminary Results in Ondansetron Study

  4/10/2012

• SCOLR Pharma, Inc. Provides Product Information on Website

  3/6/2012

• SCOLR Pharma, Inc. Launches Cutting Edge Nutritional Products at Major Retailers in 2012

  2/17/2012

• SCOLR Pharma, Inc.'s Partner to Commence Bioequivalence Study of Ondansetron

  2/15/2012

• SCOLR Pharma, Inc. Announces Initial Shipments of Its Nutritional Products

  12/28/2011

• SCOLR Pharma, Inc. Announces Third Quarter 2011 Financial Results

  11/11/2011

• SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results

  7/27/2011

• SCOLR Pharma, Inc. Announces Final Closing of Private Placement

  7/1/2011

• SCOLR Pharma, Inc. Announces Initial Closing of Private Placement

  6/17/2011

• SCOLR Pharma, Inc. First Quarter 2011 Financial Results

  5/10/2011

• SCOLR Pharma, Inc. to Present at Taglich Brothers 8th Annual Small Cap Equity Conference

  5/3/2011

• SCOLR Pharma, Inc. to Present at Taglich Brothers 8th Annual Small Cap Equity Conference

  4/28/2011

• SCOLR Pharma, Inc. Signs New Lease Amendment and Lowers Severance Amounts in Executive Contracts

  4/27/2011

• SCOLR Pharma, Inc. to Present at Taglich Brothers 8th Annual Small Cap Equity Conference

  4/13/2011

• SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs

  3/30/2011

• SCOLR Pharma, Inc. Receives Deficiency Letter from FDA on Pseudoephedrine Application

  3/14/2011